Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease | Forma Therapeutics, Inc | Ongoing | FT-4202 | 2/3 | 4202-HEM-301 | King Khalid University Hospital (Riyadh),Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia |
| EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy | Novartis Saudi Limited | Completed | BYL719 / Alpelisib | 2 | CBYL719C2202 | King Fahad Specialist Hospital (Dammam),King Khalid University Hospital (Riyadh) |
| Multinational Survey-Based Chart Review Study in International Markets to Evaluate the Effectiveness, Safety, and Treatment Patterns of DUPIXENT® (Dupilumab) in Patients with Moderate-to-Severe Atopic Dermatitis | Sanofi-Aventis group | Completed | DUPIXENT® (Dupilumab) | 4 | DUT0012 | Specialized Medical Center (Riyadh),Dr. Erfan & Bagedo General Hospital (Jeddah) |
| A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE) | Agios Pharmaceuticals, Inc. | Ongoing | Mitapivat | 3 | AG348-C-017 | King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Hospital NG (Al Ahsa) |
| A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE-T) | Agios Pharmaceuticals, Inc. | Ongoing | Mitapivat | 3 | AG348-C-018 | King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Hospital NG (Al Ahsa) |
| A Multi-Country Observational Retrospective Study to Evaluate the Prevalence of PD-L1 and its Role in Patients with TNBC Treated with Systemic Therapy (VANESSA) | Hoffmann-La Roche Ltd | Terminated | N/A | 4 | MO42921 | King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh) |
| A multi-centre, prospective, non-interventional single-arm study investigating clinical parameters associated with the use of once-daily oral semaglutide in a real-world adult | Novo Nordisk | Ongoing | Oral semaglutide (Rybelsus®) | 4 | NN9924-4542 | Specialized Medical Center (Riyadh),My Clinic (Jeddah),Dallah Hospital (Riyadh),Dr. Sulaiman Al-Habib Medical Group (Riyadh),Dr. Soliman Fakeeh Hospital (Jeddah),Saudi German Hospital (Jeddah),Almoosa Hospital,Mouwasat Hospital |
| A Retrospective Chart Review Combined with a Prospective Cross-sectional Survey and Interviews on Patients with Type 2 Diabetes Mellitus to Assess Effectiveness of Adding SodiumGlucose Co-transporter 2 Inhibitor to Gliclazide Modified Release | ervier Affaires Médicales | Ongoing | SodiumGlucose Co-transporter 2 Inhibitor added to Gliclazide Modified Release | 4 | DIM-05762 | King Khalid University Hospital (Riyadh),King Abdulaziz University Hospital (Jeddah),Ghassan Najeeb Pharaon hospital (Jeddah) |
| A Real-World Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Patients Receiving Dupilumab Therapy, with Atopic Dermatitis Control Tool in Gulf Countries | Sanofi | Ongoing | Dupilumab (Dupixent) | 4 | OBS17399 | King Abdulaziz University Hospital (Jeddah),Saudi Airlines Medical Service Center,Dr. Erfan & Bagedo General Hospital (Jeddah),Specialized Medical Center (Riyadh),JC Clinics Complex – Jeddah,Saudi German Hospital (Jeddah),Sulaiman Al Habib Hospital - Al Khobar,King Fahad Medical City (Riyadh),King Faisal General Hospital (Makkah),Al Mana Hospital,King Abdul Aziz Hospital (Makkah) |
| A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | Astrazeneca | Ongoing | Trastuzumab-deruxtecan | 3 | D967RC00001 | International Medical Center (Jeddah),King Fahad Specialist Hospital (Dammam) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.